<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="cd19-tafa-inmind-alvarez-arias-pf1006">
    <meta name="study:title" content="PF1006 - CD19 expression is retained in patients with relapsed/refractory follicular or marginal zone lymphoma after receiving tafasitamab, lenalidomide and rituximab in the inMIND study">
    <meta name="study:fileName" content="Abstracts/CD19-TAFA-INMIND-ALVAREZ-ARIAS-PF1006.html">
    <meta name="study:cancerTypes" content="FL,MZL,B-NHL">
    <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Tafasitamab,Lenalidomide,Rituximab,Monoclonal Antibody,Immunomodulatory drugs,CIT">

    <title>PF1006: CD19 Expression with Tafa+L+R (inMIND Study)</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="embargo-notice">
            <p><strong>EMBARGOED:</strong> This abstract is embargoed until Thursday, June 12, 2025, 08:00 CEST.</p>
        </div>

        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PF1006 - CD19 Expression after Tafa+L+R in R/R FL/MZL (inMIND)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (inMIND Sub-analysis)</h4>
                    <p>R/R FL or MZL pts (N=654 enrolled). Aim: Explore impact of Tafa+L+R vs Pbo+L+R on CD19/CD20 expression, B-cells, MRD.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (inMIND Trial)</h4>
                    <p>Tafasitamab + Lenalidomide + Rituximab (Tafa+L+R) vs Placebo + Lenalidomide + Rituximab (Pbo+L+R).</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M17.25 9.11v5.38a4.502 4.502 0 01-4.5 4.5h-3a4.502 4.502 0 01-4.5-4.5V9.11A4.502 4.502 0 019.75 4.61h.046a4.5 4.5 0 014.408 4.065 2.25 2.25 0 004.419.426.75.75 0 00-1.34-.504 2.25 2.25 0 00-4.075-1.316 3.001 3.001 0 00-2.965-2.632H9.75A4.502 4.502 0 0114.25 0h.09a4.502 4.502 0 014.41 4.41v4.7zM5.25 12A2.25 2.25 0 003 14.25v3A2.25 2.25 0 005.25 19.5h3A2.25 2.25 0 0010.5 17.25v-3A2.25 2.25 0 008.25 12h-3z" />
                    </svg>
                    <h4>Key Finding: CD19 Expression</h4>
                    <p>CD19 antigen <span class="highlight-value">preserved</span> on tumor cells at EOT after Tafa+L+R (IHC & sequencing). No CD19/CD20 correlation with response.</p>
                </div>
                <div class="visual-abstract-item">
                   <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zM12.75 6a.75.75 0 00-1.5 0v6c0 .414.336.75.75.75h4.5a.75.75 0 000-1.5h-3.75V6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Conclusion</h4>
                    <p>CD19 antigen is largely retained following Tafa+L+R in R/R FL/MZL, supporting potential for sequential CD19-targeted therapies.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PF1006: CD19 expression is retained in patients with relapsed/refractory follicular or marginal zone lymphoma after receiving tafasitamab, lenalidomide and rituximab in the inMIND study</h1>
            <p class="abstract-sub-header">Sarah Reinke, Wolfram Klapper, Oscar Bortolami, TaeHyung Kim, Diana Alvarez Arias</p>
            <p class="abstract-meta-info mt-2">EHA Library PF1006 | Abstract Release: 05/14/2025 | Presentation: 06/13/2025</p>
        </div>

        <div class="grid md:grid-cols-12 gap-x-8 gap-y-6">
            <div class="md:col-span-8">
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-2 pl-2">
                        <li>Frontline FL treatment often uses anti-CD20 mAbs (e.g., Rituximab [R]) Â± chemotherapy.</li>
                        <li>Immunotherapies like Lenalidomide (L) + R are preferred for R/R FL, but durability needs improvement.</li>
                        <li>CD19 is expressed in FL and is a target for therapies (e.g., CAR-T), but CD19 antigen loss is a concern for sequential CD19 targeting.</li>
                        <li>Tafasitamab (Tafa) is an Fc-enhanced, CD19-targeting mAb, approved with L for R/R DLBCL.</li>
                        <li><strong>inMIND Study (NCT04680052):</strong> Phase 3 trial evaluating Tafa+L+R vs Placebo (Pbo)+L+R in R/R FL or MZL.
                            <ul class="list-circle list-inside ml-4 mt-1">
                                <li>Met primary endpoint: prolonged PFS for Tafa+L+R in FL pts (Sehn LH. Blood. 2024; LBA1).</li>
                            </ul>
                        </li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm">To explore the impact of Tafa+L+R and Pbo+L+R on CD19 and CD20 expression and how this correlates with treatment response; and to assess the impact of treatments on B-cell counts and depth of response (minimal residual disease [MRD]).</p>
                </div>
                
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods (inMIND Pharmacodynamic Sub-analysis)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li><strong>Study Design:</strong> Pharmacodynamic analysis from the Phase 3, double-blind, randomized, placebo-controlled inMIND trial.</li>
                        <li><strong>Patient Population:</strong> Patients with R/R FL or MZL.</li>
                        <li><strong>B-cell Counts:</strong> Assessed by flow cytometry (IQVIA).</li>
                        <li><strong>CD19/CD20 Expression:</strong>
                            <ul class="list-circle list-inside ml-4 mt-1">
                                <li>Tumor biopsies assessed centrally by Immunohistochemistry (IHC).</li>
                                <li>Anti-CD19 mAb: BT51E clone.</li>
                                <li>Anti-CD20 mAb: L26 clone.</li>
                            </ul>
                        </li>
                        <li><strong>CD19 Sequencing:</strong> Performed using NovaSeq6000 (NeoGenomics) on blood or BMA samples from MRD positive pts.</li>
                        <li><strong>MRD Assessment:</strong> Measured in peripheral blood (PB) and bone marrow aspirate (BMA) by IgH clonality and somatic hypermutation assay (NeoGenomics).</li>
                    </ul>
                </div>
            </div>

            <div class="md:col-span-4">
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient & Sample Overview</h2>
                    <div class="table-container compact-table">
                        <table>
                            <thead>
                                <tr><th>Parameter</th><th>Value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Pts Enrolled (inMIND)</td><td>654</td></tr>
                                <tr><td>Screening Biopsies Available</td><td>622 (95%)</td></tr>
                                <tr><td>EOT/Follow-up Samples (CD19/20 IHC)</td><td>32</td></tr>
                                <tr><td>CD19 Sequencing Samples (MRD+ Tafa Arm)</td><td>28</td></tr>
                            </tbody>
                        </table>
                    </div>
                </div>
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Key Findings: CD19 & CD20 Expression</h2>
                    <h3 class="abstract-sub-section-title">At Screening:</h3>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>CD19 expression was 100% in 86% of screening biopsies.</li>
                        <li>2 pts were CD19-negative at screening.</li>
                        <li>8 pts were CD20-negative at screening.
                            <ul class="list-circle list-inside ml-4 mt-1">
                                <li>Tafa+L+R arm (n=4): 4/4 responded (3 CR, 1 PR).</li>
                                <li>Pbo+L+R arm (n=4): 2/4 responded (1 CR, 1 PR).</li>
                            </ul>
                        </li>
                        <li>Expression of CD19 or CD20 (alone or together) did not correlate significantly with response.</li>
                    </ul>
                     <h3 class="abstract-sub-section-title mt-2">At End of Treatment (EOT) / Follow-up (N=32 samples):</h3>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Tumor cells detected: 62% (8/13) in Tafa+L+R arm vs 84% (16/19) in Pbo+L+R arm.</li>
                        <li><strong>All EOT samples with tumor cells were CD19 positive by IHC</strong>, except 1 pt refractory to R in Tafa+L+R arm.
                            <ul class="list-circle list-inside ml-4 mt-1">
                                <li>This exceptional pt (80% CD19-neg at screening) achieved PR, suggesting elimination of CD19+ cells.</li>
                            </ul>
                        </li>
                    </ul>
                    <h3 class="abstract-sub-section-title mt-2">CD19 Sequencing (N=28, MRD+ Tafa Arm):</h3>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>No CD19 somatic mutations identified.</li>
                    </ul>
                </div>
            </div>
        </div>
        
        <div class="grid md:grid-cols-12 gap-x-8 gap-y-6 mt-6">
            <div class="md:col-span-full"> <div class="abstract-card">
                    <h2 class="abstract-section-title">Other Findings</h2>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li><strong>Peripheral B-cell Counts:</strong> Decreased in both arms (median 0.0210 GI/L for Tafa+L+R and 0.0315 GI/L for Pbo+L+R at baseline; 0 GI/L for each arm on treatment).</li>
                        <li><strong>MRD Assessment:</strong> IgH clonality detected in 25% of PB and 34% of BMA samples. Results were inconclusive due to a small number of evaluable pts.</li>
                    </ul>
                </div>
            </div>
        </div>


        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-2 pl-2">
                <li>In patients with R/R FL or MZL enrolled in the inMIND study, analyses of biopsies and CD19 sequencing suggest that the <strong>CD19 antigen is preserved on tumor cells</strong> following treatment with Tafasitamab+L+R.</li>
                <li>Neither CD19 nor CD20 expression, alone or in combination, correlated significantly with response to Tafa+L+R.</li>
                <li>These findings support the potential for sequential CD19-targeted therapies in this patient population.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>
                BMA, Bone Marrow Aspirate; CAR-T, Chimeric Antigen Receptor T-cell; CD, Cluster of Differentiation; CR, Complete Response; EOT, End of Treatment; FL, Follicular Lymphoma; GI/L, Giga/liter; IgH, Immunoglobulin Heavy Chain; IHC, Immunohistochemistry; L, Lenalidomide; mAb, Monoclonal Antibody; MRD, Minimal Residual Disease; MZL, Marginal Zone Lymphoma; PB, Peripheral Blood; Pbo, Placebo; PFS, Progression-Free Survival; PR, Partial Response; Pts, Patients; R, Rituximab; R/R, Relapsed/Refractory; Tafa, Tafasitamab.
            </p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" class="w-4 h-4 mr-1.5">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">
                Alvarez Arias D, Reinke S, Klapper W, et al. CD19 expression is retained in patients with relapsed/refractory follicular or marginal zone lymphoma after receiving tafasitamab, lenalidomide and rituximab in the inMIND study. Abstract #PF1006 presented at European Haematology Association (EHA) June 13, 2025, City, Country.
            </p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA Library PF1006 | Presentation Date: 06/13/2025</p>
            <p>For Research & Informational Purposes Only. This abstract is embargoed until Thursday, June 12, 2025, 08:00 CEST.</p>
        </div>
    </div>
    <script defer src="abstract_features.js"></script> 
</body>
</html>
